Using Microbubbles as Targeted Drug Delivery to Improve AIDS by Sonaye, Harsha Virsingh et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Using Microbubbles as Targeted 
Drug Delivery to Improve AIDS
Harsha Virsingh Sonaye, Rafik Yakub Shaikh  
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Abstract
No preventive vaccines are available for the treatment of AIDS. To improve 
therapy, combinational antiretroviral drugs are given; however some patients 
develop resistance to particular combinational drug. Microbubble-mediated drug 
delivery technology solves the problem by reducing systemic dose and toxicity. 
Microbubbles are bubbles smaller than one millimeter in diameter but larger than 
one micrometer. The general composition of microbubble is gas core. The mecha-
nism of microbubbles through which its delivery increases is sonoporation, the 
formation of openings in the vasculature, induced by ultrasound-triggered oscil-
lations and destruction of microbubbles. Rapid isolation strategy of CD4+ cells is 
mixing blood and glass microbubbles which then bind with the specific target cells 
to the microbubble carrying specific antibodies on their surface. The target cells 
will spontaneously float to the top of the blood vial and can be quickly separated. 
The microbubbles are particularly used in the diagnosis of AIDS because of their 
cell isolation techniques which is rapid and inexpensive and their small size to pass 
through capillary for perfusion in tissue This review demonstrates the problems 
with the current treatment of the disease and shed light on the remarkable potential 
of microbubbles to provide more effective treatment and prevention for HIV/AIDS 
by advancing antiretroviral therapy, gene therapy, immunotherapy, vaccinology, 
and microbicides.
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1. Introduction
The recent advanced methods of noninvasive delivery of therapeutic agents are 
effective in gene therapy and molecular biology. Besides the well-known applica-
tion of microbubbles have been demonstrated an effective technique for targeted 
delivery of drugs and genes and is also used as contrast agents for diagnostic 
ultrasound [1–6]. A schematic structure of the biomedical microbubble is shown 
in Figure 1. The size of microbubbles is larger than micrometer but smaller than 
one hundredth of millimeter in diameter which is equal to the size of red blood cell. 
Because of its smaller size, it can pass in the microvessels and capillaries throughout 
the body. In aqueous environment, the microbubbles are unstable and show surface 
tension effect because of this properly it require the shell and filling material. The 
gas core of microbubbles gets stabilized by lipid, protein, and polymers [7, 8]. In 
water microbubbles are miniature gas bubbles of less than 50 microns diameter.  
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It mostly contains oxygen or air and remains suspended in the water for an 
extended period. The gas present in the microbubbles dissolves into the water, and 
the bubble disappears. Incorporation of drug in microbubble includes (1) binding 
of drug to microbubble shell and (2) attachment of drug at specific site of ligand. In 
ultrasound-mediated microbubbles, application of high intensity ultra sound can 
rupture capillary blood vessels resulting in deposit of protein and genetic material 
into the tissue, ultrasonic rupture of microvessels with diameter 7 μm. Ultrasound 
forms pores in the membrane of shell. Ultrasound microbubble causes transient 
hole in the cell surface resulting in rapid translocation of plasmid DNA from the 
outside to cytoplasm. Low-intensity ultrasound microbubble (0.6 W/cm2) caused 
enhanced drug delivery [55]. Microbubbles are usually injected intravenously 
which is a safe process as compared to the use of conventional method like magnetic 
resonance imaging and radiography. Microbubble is used in the medical field as 
diagnostic aids to scan the various organs of the body, and recently they are being 
proposed to be used as drug or gene carriers and also for treatment in cancer 
therapy. It is also used to improve the fermentation of soil, to increase the hydro-
ponic plant growth, to increase the aquaculture productivity, and to improve the 
quality of water, in sewage treatment.
2. Compositions and physicochemical properties of microbubbles
2.1 Protein as stabilizing agent in formation of microbubbles
Albumin-shelled microbubbles were a pioneering formulation used in contrast 
ultrasound imaging. For perfusion in capillary and microvessels, albumin-shelled 
microbubbles are very effective. The size of albumin-shelled microbubbles ranges 
from 1 to 15 μm in diameter in 7 × 108 microbubbles/mL which is stable for 2 years. 
To formulate albumin-coated microbubbles by sonication method, 5% w/v human 
serum albumin with air is required and encapsulated within 15 nm thick shell of 
aggregated albumin. For better encapsulation process, the denaturation of albumin by 
heating is essential [9, 10]. The albumin shell is held together through disulfide bonds 
between cysteine residues formed during cavitation [11]. Covalent cross-linking 
may explain the relative rigidity of albumin shells observed during ultrasonic insoni-
fication [12]. Apart from albumin, several proteins are used to coat microbubbles. 
Figure 1. 
Illustration describe various shell compositions of microbubbles. The diameter between 0.5 and 10 μm is applied 
for biomedical use so that it can pass through the capillary of the lung. Microbubbles compose of total particle 
volume which act as single chamber so that the shell of the microbubble separate encapsulated gas and the 
surrounding aqueous medium by using various shell materials like lipid with thickness~3 nm thick, protein 
having 15–20 nm thick and polymer of 100–200 nm thick. Hydrophobic and Vander Waals interactions binds 
the lipid molecule together and by covalent disulphide bonding the protein molecules get cross-linked so that the 
formation of bulk like material.
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The proteins which are amphipathic in nature are highly surface-active. In most of 
the proteins, the disulfide bridge between two thiol groups is present. Cavalieri and 
co-workers prepared microbubbles by using lysozyme which retain their enzymatic 
activity for several months and found to be stable [13]. Korpanty et al. [14] developed 
microbubble by incorporating avidin into albumin shell. Figure 2A illustrates target-
ing vascular endothelium in biotin-mediated coupling of antibodies.
2.2 Surfactant as stabilizing agent in formation of microbubbles
SPAN-40 and TWEEN-40 are used as stabilizing agent in the preparation 
of microbubbles [15, 16]. For the formation of stable microbubbles, the SPAN/
TWEEN solution was sonicated in the presence of air. For maximum film stability, 
a Langmuir trough was used in the ratio of SPAN to TWEEN (roughly 1:1). By using 
sonicated microbubbles, modified surfactant was formed which was more stable 
film due to higher collapse pressure on the Langmuir trough [16]. Dressaire et al. 
recently reported stable microbubbles formed from a blending process at 70°C in 
75 wt% glucose syrup, sucrose stearate (mono- and di-ester) formed [17].
2.3 Lipid as stabilizing agent in the formation of microbubbles
For biomedical imaging and drug delivery, lipid-coated microbubbles are one of 
the most interesting and useful formulations. The lipid shell is inspired by nature, 
as stable microbubbles found ubiquitously in the oceans and freshwaters of earth 
are known to be stabilized by acyl lipids and glycoproteins [18].
During ultrasound and sonication technique, the lipid molecules which are 
held together by weak physical forces form the microbubble shell having property 
of expansion and compression without chain entanglement. Lipid-coated micro-
bubbles therefore reduce the damping effect on resonance and reseal around the gas 
core during fragmentation process [12]. Thus, the lipid-coated microbubble itself 
is a versatile platform technology. An example of lipid microbubble is shown in 
Figure 2B, which depicts heterogeneity and phase separation of phosphatidylcho-
line and lipopolymers that are typically used to stabilize lipid microbubble [19].
2.4 Polymer as a stabilizing agent in the formation of microbubbles
The term, “polymer microbubble” typically refers to a special class of micro-
bubbles that are stabilized by a thick shell comprising cross-linked or entangled 
polymeric species. Polymer shells are more resistant to expansion and compression; 
Figure 2. 
Microbubble shell morphologies. (A) A lysozyme protein microbubble imaged with SEM (Calaveri et al. 
(13)). The microbubble diameter is roughly 1 μm. (B) A diC20:0 phospholipid microbubble imaged with 
fluorescence microscopy taken from Borden et al. Scale bar denotes 20 μm. (C) A PLA-PFO polymer 
microbubble imaged with SEM.
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therefore during drug delivery, it reduces echogenicity. During insonification 
polymer microbubbles release gas core which was unstable and rapidly dissolved  
[8, 20]. In 1990 a new polymer-shelled microbubble was reported by Wheatley et al. 
[21] in which the shell was formed by the ionotropic gelation of alginate. By using 
concentric jells of air and alginate solution, the microbubbles were prepared that 
was sprayed into a reservoir. On plunging into the calcium solution, the alginate was 
absorbed by the gas/liquid interface and was hardened. To increase the microbubble 
yield, sonicate the solution prior to spraying. By using the flow rate of air around 
the syringe needle, microbubble size was primarily determined. The diameters of 
microbubbles ranged between 30 and 40 μm and were therefore too large for intra-
venous administration. In 1997, Bjerknes et al. [22] introduced a method for making 
microbubbles using an emulsification—solvent evaporation method—encapsulated 
by a proprietary double-ester polymer with ethylidene units. The polymer micro-
bubbles had a diameter ranging from 1 to 20 μm diameter. Optical microscopy and 
cryogenic transmission electron microscopy (cryo-TEM) were used for the determi-
nation of elongated, crumpled shapes of the microbubbles. The polymer shell was 
typically 150–200 nm thick. Acoustic tests determine a dose-dependent increase in 
acoustic attenuation. In 1999, Nayaran and Wheatley describe the preparation of 
microbubbles by using the biodegradable copolymer poly(D,L-lactide-co-glycolide) 
(PLGA). By using a volatile solid core, the microspheres were made hollow which 
could be sublimed. Manipulation of the solution viscosity, polydispersity, and 
shearing rate microbubble size was controlled. The size distribution ranged from 2 
to 20 μm diameter. After incubation in serum the zeta potential of the microbubbles 
became less negative. In 2005, Cui et al. [23] reported the fabrication of PLGA 
microbubbles by using a double emulsion, solvent evaporation method. Coulter 
counter determines the size ranges between 1 and 2 μm diameter. Scanning electron 
microscopy (SEM) is used to study surface of particles so that the smooth surfaces, 
visible pores, or cavities can be explained. Confocal scanning microscopy explains 
internal morphology so that a single hollow core to a more honeycomb structure 
could be explained depending on the emulsification conditions. In 2005, Cavalieri 
et al. [24] determined a method of coating microbubbles by using PVA. In this case 
chemical cross-linking of PVA with microbubbles occurs at the air/water interface 
with a speed of 8000 rpm, so the mean diameter was approximately 6 ± 1 μm. 
By decreasing the operating temperature from room conditions to 4°C, the shell 
thickness could be decreased from 0.9 to 0.7 μm. PVA microbubbles enhance the 
shelf life of microbubbles by several months. This also increases the incorporation 
capability of hydrophobic drug and targeting ligand in microbubbles. Bohmer et al. 
[25] in 2006 used inkjet printing and developed a new technique for the preparation 
of polymer microbubbles. In this method they injected copolymer polyperfluo-
rooctyl oxycaronyl-poly (lactic acid) (PLA-PFO) having a diameter of 4–5 μm as an 
organic phase into the aqueous solution (Figure 2C).
2.5 Microbubbles used as polyelectrolyte multilayer shells
Polyelectrolyte multilayer (PEM) is a modified type of polymer surfactant 
shell for the formulation of perforated microbubbles. These microbubbles are 
coated with charged surfactant which acts as a substrate. To absorb oppositely 
charged polymer, the layer by layer assembly technique is used [26]. Borden 
et al. [27] used trimethylammonium propane (TAP) which is a phospholipid 
containing the cationic head group for creating PEM microbubble where TAP 
serves as shell. Lentacker et al. [28] described multilayer microbubble. The 
coating material is DNA and PAH which protect the DNA from enzymatic 
degradation.
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3. Types
1. Perfluorocarbon-filled microbubble, which is stable for circulating in the 
vascular system as blood pool act as carrier.
2. Ultrasound microbubble, when applied over skin surface where it bursts and 
releases drug. It is use in low concentration. It also increases therapeutic index. 
It is advantageous for those drugs which have hazardous and toxic effect.
3. Albumin-encapsulated microbubble, which adheres to vessel walls.
4. Phospholipid-coated microbubble, which has a high affinity for chemothera-
peutic drugs [55].
4. Applications
1. Microbubbles increase adherence to damaged vascular endothelium. As the 
viral proteins obtain in immune response within target tissue the use of viral 
vector is limited in gene therapy. It has been seen that viral vector causes an 
intense inflammatory activation of endothelial cells [55].
2. Ultrasound when applied over the skin surface bursts the microbubbles which 
causes localized release of drug [29–32]. This technique require lower con-
centration of drug systemically and the concentration of drug only where it is 
needed therefore the therapeutic index may be increased which is advantageous 
in case of drug with hazardous systemic side such as cytotoxic agents [33].
3. In diagnostic ultrasound, microbubbles create an acoustic impedance mis-
match between fluids and tissues to increase reflection of sound which is used 
in radiology and cardiology for the detection of perfusion and characteriza-
tion of tissues. Microbubbles not only increase reflection of sound, they also 
increase the absorption of sonic energy [34].
4. Ultrasound to contrast agents creates extravasation points in skeletal muscle 
capillaries. High-intensity ultrasound can rupture capillary vessel resulting 
in the deposition of protein and genetic material into the tissues. Only a small 
capillary rupture was required to deliver large quantities of colloidal particles 
to the muscles [35].
5. Ultrasound increases the transmembrane current as a direct result of mem-
brane resistance due to pore formation [36].
6. Ultrasound-induced cavitation may then be used to destabilize the carriers 
and affect local drug release. Applications of sonodynamic therapy may 
include tumor ablation and treating vascular disease such as atherosclerotic 
plaques. To make targeted microbubbles, targeting ligands were developed 
and were called bioconjugates suitable for incorporation into membranes 
stabilizing microbubbles.
7. The anchor locks the bioconjugate into the membrane surrounding the 
microbubble, and the linker gives the peptide-based targeting ligand enough 
motional freedom to bind to its target (see Figure 3). Thrombus-specific 
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peptides, directed to the activated GP2B3A receptor of platelets, were evalu-
ated for affinity to bind to activated platelets by testing for the inhibition of 
platelet aggregation.
In Figure 3 the outer surface is stabilized by amphipathic lipid. Targeting ligands 
have been incorporated onto the head groups of the lipids. The genetic material is 
stabilized by cationic lipids. Electron microscopy studies have shown that the DNA 
is condensed as an electron-dense granule within the center of the nanoparticle. 
The diameter of these particles is about 100–200 nm [37]. There are several advan-
tages to lipid shells. At the air-Space minimized, the phopspholipid’s hydrophobic 
acyl chains face the phopspholipid’s gas, and hydrophilic head groups face the water. 
Thus the monolayer will form around a newly trained gas bubble. Saturated diacyl 
phospholipids have very low surface tension below phase transition temperature. 
This is essential as surface tension at the curved interface induces a Laplace over-
pressure, thus forcing the gas core to dissolve [8]. The microbubble stabilizes at 
low tension which is achieved by the lipid monolayer [38]. Monolayers of lipids are 
highly cohesive and form solid-like character because of the attractive hydrophobic 
interaction between the tightly packed acyl chains and van der Waals [39]. These 
effect can be effective because the stability of microbubbles during sonication is not 
dependent on superoxide formation to facilitate disulfide bridging, as is the case 
with proteins. Therefore, as recently described by Stride and Edirisinghe, lipids are 
suitable for a variety of manufacturing techniques apart from sonication [40].
In the absence of ultrasound, if the adenovirus was administered with micro-
bubbles using the same model, the author confirmed that plasmid transgene expres-
sion can be directed to the heart, with an even higher specificity than viral vectors 
and that this expression can be regulated by repeated treatments [41]. Lu et al. [42] 
have also shown that albumin-coated microbubbles significantly improved transgene 
expression in skeletal muscle of mice, even in the absence of ultrasound.
5. Mechanisms for target drug delivery using microbubbles
Based on the cavitation of microbubbles, two possible strategies for deliver-
ing drugs and genes with microbubbles are emerging: the first consists on the 
ultrasound-mediated microbubble destruction and the second is the direct delivery 
Figure 3. 
Liquid perfluorocarbon gene carrier.
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of substances bound to microbubbles in the absence of ultrasound. Different drugs 
and genes can be integrated into the ultrasound contrast agent such as perfluoro-
carbon-filled albumin microbubbles which actively bind proteins and synthetic 
oligonucleotides [43]. Microbubbles can directly take up genetic material, such as 
plasmids, adenovirus, and phospholipid-coated microbubbles as these have high 
affinity for chemotherapeutic drugs.
6. Mechanism by ultrasound-mediated microbubble destruction
Ultrasound facilitates the delivery of drugs and genes. In the insonified field, 
the presence of microbubbles reduces the peak negative pressure which is necessary 
to enhance drug delivery. This happened because microbubbles acting as nuclei for 
cavitations decrease the threshold of ultrasound energy. Microbubble gets destroyed 
by ultrasound due to the gradual diffusion of gas at low acoustic power, formation of 
a shell defect with diffusion of gas, immediate expulsion of the microbubble shell at 
high acoustic power, and dispersion of microbubbles into several smaller bubbles.
7. Mechanism by cavitation of the bubbles
It is characterized by rapid destruction of contrast agents due to a hydrodynamic 
instability during large amplitude oscillations, and is directly dependent on the 
transmission pressure [43]. Cavitation of the microbubbles increases capillary perme-
ability and delivery of material to the interstitial tissue. When cavitation occurs, this 
may impart a ballistic effect to drive the drug from the vasculature into or through the 
vessel wall. Cavitation events will be intimately associated with the drugs themselves 
(Figure 4) [34]. There are two mechanisms for drug delivery in microbubbles that are 
incorporation of drug and drug release from these microbubbles.
Figure 4. 
Different ways microbubbles can transport drugs. Drugs may be attached to the membrane surrounding the 
microbubble. (a) Drugs may might also be formulated to load the interior with drug and gas, or be imbedded 
within the membrane itself. (b) Materials, e.g. DNA, may be bound noncovalently to the surface of the 
microbubbles. (c) Microbubbles hydrophobic drugs can be incorporated into a layer of oily material that forms 
a film around the microbubble, which is then surrounded by a stabilizing membrane. (e) In this example a 
targeting ligand is incorporated on the membrane allowing targeted delivery of the drug. Note that although in 
these examples the stabilizing materials are shown as lipids, but could also be polymeric materials [33].
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1. Drug incorporation into microbubbles: incorporation of drug molecule in 
the microbubbles in a following way (1) incorporation of drug molecule only 
within bubble, (2) incorporation of drug molecule within cell membrane, (3) 
attachment of drug molecule to microbubbles by covalent bonds, (4) attach-
ment of drug molecule to microbubbles by ligand (ex avidin-biotin complex), 
and (5) incorporation of drug molecule in multiple layer of microbubbles. 
Microbubbles are able to cross the BBB through above process.
In Figure 3 by attaching a targeted ligand such as monoclonal antibody a 
targeted microbubbles are developed. These are specific for endothelial marker 
as microbubbles. To assess vascular pathology targeted ultrasound contrast 
agent are used ex: P-selectin, ICAM-1, GpIIb/IIIa, the αv integrins.
2. Release of drug from microbubbles: microbubbles on application of ultra-
sound undergo a process known as cavitation. Ultrasound causes the microbub-
ble to burst or break. The body fluids begin to insonate on cavitation to create 
acoustic cavitation. After oscillating microbubbles produces increase small 
eddy, this increases the permeability of cell membrane and drug passes across 
the membrane. Microbubbles also release the drug by phagocytosis mechanism. 
Figure 5 describe the delivery of drug through fusion mechanism in which the 
phospholipid microbubble fuse with phospholipid bilayer of cell membrane 
and releasing of drug or gene into the cytoplasm of cell membrane. By this 
mechanism the gene get directly transfer to the nucleus of the cell [44–47].
8. Advancements in nano-enabled therapeutics for HIV management
Human immunodeficiency virus (HIV) is a deadly infectious disease world-
wide [48–50]. The World Health Organization confirms 0.35 million HIV-infected 
people. Apart from them, 28 million people are eligible for antiretroviral therapy 
(ART and only 11.7 million could afford antiretroviral (ARV) drugs. But the 
ultimate challenge in highly active ART is the elimination of HIV-1 reservoirs 
from the peripheral nervous system and central nervous system (CNS) [51]. 
The integration of HIV-1 genome with host genome causes viral latency in the 
Figure 5. 
Drug release from microbubbles by cavitation.
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periphery and in brain. However, the inability of ART to penetrate the blood–
brain barrier (BBB) after systemic administration makes brain as one of the most 
dominant HIV infection reservoirs [48]. Recently, dual therapy, i.e., an optimized 
cocktail of two ARV drugs, has been introduced to manage HIV infection by 
Kelly et al. [52]. The authors claimed that the dual therapy containing tenofovir 
(TEF) exerted more therapeutic advantages than triple therapy. Furthermore, the 
selection of appropriate drug according to the patient condition is very essential 
because this therapy may reduce virologic efficacy in HIV-infected patient while 
lowering CD4 counts per high pre-ART HIV-1 RNA level. This report stated that 
new nanoformulations (NFs) of LA cabotegravir (CTG) and rilpivirine (RPV) 
may have bright future aspect for HIV therapeutics. This viable dual therapy 
is useful to manage ART options and performance, which lowers the costs and 
the globally unmet needs of pill-fatigued and adherence-challenged individu-
als [52]. The pharmacologic profile of CTG has great potential for the treatment 
and prevention of HIV-1 infection. This drug has half-life of 40 days and at a low 
dose showed therapeutic action, so that monthly and bimonthly oral administra-
tion in the form of tablet would be enough to control HIV infection [53]. As the 
significant advancement made in antiretroviral drug for HIV very few efforts 
have been developed for effective anti HIV vaccine [54]. To cure neuro HIV the 
inability of effective anti HIV therapeutic agents to cross the complex integrity 
of the BBB is the major challenge, so neuro HIV is incurable in the brain. Specific 
receptor binding, focused ultrasound, microbubble assisted focused ultrasound 
and magnetic field based approaches have been demonstrated to open the BBB for 
the delivery of therapeutic agents. Due to bigger in size receptor-functionalized 
therapeutic cargos affect efficacy whereas an externally stimulated approach 
results in transient BBB opening, which may also allow the delivery of unwanted 
agents to the brain [55].
Fluoresce activated cell sorting (FACS) is a standard method for diagnosis of 
AIDS but having high cost and beneficial only in area where large number of HIV 
patient resides. The second standard technique is Magnetic activated cell sorting 
(MACS) used for CD4 cell counting. It involves mixing of sample with magnetic 
beads which get attached to anti bodies. AIDS can be monitored by using the 
microbubbles which require no expensive equipment and low cost as compare to 
above methods. In this technique for separation of CD4 T cell lymphocyte from 
whole blood cell microbubbles are used. By mixing target specific antibody with 
microbubbles, the microbubbles get float on surface and provide eminent contact 
between microbubbles and target cell so that target cell attach to microbubbles 
while non-targeted cell at the bottom side due to gravity [56].
Ultrasound in presence of microbubbles increases plasmid transfusion effi-
ciency in-vitro. Microbubbles form pores upto 100 nm by cavitation mechanism 
which is having short half life. Loading microbubbles with nucleic acid and /or 
disease targeting ligand may improve efficiency and specificity. Generation of 
reversible pore in the plasma membrane due to sonoporation increased plasma 
membrane permeability to marker compounds. Recent studies state that the effect 
of low frequency 20 Hz by ultrasound on uptake of fluorescent dye calcein having 
molecular weight 623 Da and radius 0.6 μm into mouse increase cavitation. This 
data explains that cavitation occur during insonication influence the membrane 
permeability. Practical and theoretical experiment on microbubble state that the 
rapid bubble expansion collapse and subsequent shock wave formation can gener-
ate shear forces which disturb cell membrane integrity and increased permeability. 
Further, the geometry of microbubble collapse is itself influenced by adjacent cell 
membrane like microjet of the surrounding fluid which in transfection medium 
contains exogenous nucleic acid may get injected in cell [57].
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9. Conclusion
Barriers of HIV/AIDS treatment
• HIV is localized in latent cellular and anatomical reservoirs where the major-
ity of therapeutic agents are unable to completely eradicate the virus for the 
necessary duration.
• The anatomical reservoirs where the HIV get resides are CNS, the cerebrospi-
nal fluid, the lymphatic system, tests, liver, kidney, lungs, the gut and in the 
macrophage.
• Microphages act as host for viral genetic recombination where it contribute to 
the generation of elusive mutant viral genotypes
• The other barriers for current therapeutic drug regimens do not fully eradi-
ate the virus from cellular and anatomical reservoirs. In certain cases patient 
requires to take daily pills which produce patient adherence. These agents have 
side effect and in some patient resistance develops.
• Current drug therapy can lower the systemic viral load below the detection 
limit therefore on discontinuation of treatment, there is relapse of the infec-
tion occur from the reservoir sites and a potential for resistance develops.
Microbubbles-based drug delivery for HIV/AIDS treatment
• Microbubbles-based drug delivery systems produce complete eradication of 
viral load from the reservoir sites.
• Micro bubbles containing antiretroviral drugs bind to the CD4+ T cells and 
macrophages, and reach to latent reservoir of CNS, the cerebrospinal fluid, the 
lymphatic system, tests, liver, kidney, lungs, the gut and in the macrophage.
• Microbubble-based drug delivery systems deliver antiretroviral drugs in vitro 
and in vivo.
Microbubble as therapeutic agents
• Microbubbles have average size less than that of red blood cell so it get pen-
etrated into the small blood capillaries and releasing the drug.
• Microbubbles are used as tool for gene delivery.
• Microbubbles can generate strong signal so lower dose of intravenous required 
and also used in angiogenesis.
Gene therapy for HIV/AIDS treatment
• Gene therapy remove HIV completely from infected cells, as shown by reduc-
tions in the cells’ overall rate of HIV production. Gene-editing technique.
• Gene therapy based on siRNA has shown promise for HIV/AIDS treatment. 
Microbubbles platforms for delivery of siRNA for HIV/AIDS treatment are in 
their early stages but recent work has been met with optimism.
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Immunotherapy for HIV/AIDS
• Microbubbles, loaded with both antigen mRNA as well as immunomodulating 
Trimix mRNA, which can be used for the ultrasound-triggered transfection of 
dendritic cell (DC).
• DC sonoporation using microbubbles loaded with a combination of antigen and 
TriMix mRNA can elicit powerful immune responses in vivo, and might serve  
as a potential tool for further in vivo DC vaccination applications.
Microbubble used as preventive HIV/AIDS Vaccine
• New approaches are always being explored for development of an effective 
HIV/AIDS vaccine.
• For delivering DNA various polymer and lipid- based microbubbles have been 
used.
• Microbubbles encapsulate antigens in their core and cross link to antigen CD4+ 
and CD8+ T cells. These absorbing antigen allow B cell to generate responses.
• Microbubble vaccines can be given by different route of administration.
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